|
1. Purpose, background, and an overview of the study
|
|
2. Inclusion and exclusion criteria (Table 2)
|
|
3. Description of the three treatment armsa and their chances of being allocated to each one of these three arms
|
|
4. Financial aspects (no participation fee, compensation for participation)
|
|
5. Potential risks of participation and when to contact their general practitioner or a professional they can select from a medical advisory and emergency service list that will always be accessible to them, merely by clicking on the site’s Help icon
|
|
6. The inability of CANreduce-SP to replace face-to-face therapy for problematic cannabis use or abuse
|
|
7. Voluntary nature of their participation and their right to withdraw at any time without consequences, except for the loss of further compensation
|
|
8. Confidentiality and data protection (anonymity is ensured by not recording real names or postal addresses and by deleting e-mail addresses and phone numbers before statistical analysis and data archiving)
|
|
9. Protocol approval was granted by the ethics committee of the IMIM Hospital del Mar d'Investigacions Mèdiques after the committee had reviewed the study: num. 2019/8901/I.
|
